Pfizer partners with Enodia on Sec61 inhibitors in a deal worth over $500M
- Enodia will use its platform to find and develop Sec61 inhibitors against several targets; Pfizer takes on clinical, manufacturing, regulatory and commercial work.
- The upfront is undisclosed; R&D and sales milestones could push the total above $500M, with tiered royalties on top.
- It follows Lilly's deal with Gate Bioscience in the same Sec61 space, reportedly worth about $870M.
💡 Points
Sec61 is a hard target: it is a core translocon, and the chemistry has to block only disease-linked proteins without general toxicity. Two big pharmas moving within a week suggests selectivity data are persuasive behind closed doors, but the undisclosed upfront and targets mean the real signal is still thin. Watch which client proteins each company is going after.
Pfizer pens $500M Enodia pact to join Lilly in emerging protein degrader field ↗